Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Liaoning Chengda Biotechnology Co Ltd

688739:SHH

Liaoning Chengda Biotechnology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)26.88
  • Today's Change-0.40 / -1.47%
  • Shares traded1.99m
  • 1 Year change-19.59%
  • Beta--
Data delayed at least 15 minutes, as of Nov 01 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Liaoning Chengda Biotechnology Co Ltd is a China-based company mainly engaged in the research, production, and sales of human vaccines. The Company's main products include rabies vaccine for human use, freeze-dried rabies vaccine for human use, inactivated Japanese encephalitis vaccine for human use and freeze-dried encephalitis inactivated vaccine. The Company's products include two brands: Chengda Suda and Chengda Libao.

  • Revenue in CNY (TTM)1.72bn
  • Net income in CNY332.10m
  • Incorporated2002
  • Employees1.73k
  • Location
    Liaoning Chengda Biotechnology Co LtdNo. 1Xinfang Street, Hunnan New DistrictSHENYANG 110179ChinaCHN
  • Phone+86 2 483782632
  • Fax+86 2 423789772
  • Websitehttp://www.cdbio.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.58bn421.47m10.67bn1.55k25.764.08--6.771.881.887.1411.910.42861.193.671,020,281.0011.585.8616.997.5967.1255.4127.0117.200.91224.020.347727.5958.6932.2426.2029.9927.32--
Heilongjiang ZBD Pharmaceutical Co Ltd2.58bn114.60m10.70bn2.55k95.171.38--4.140.11940.11942.748.240.21181.480.76451,014,704.000.88223.481.174.7834.5238.934.1710.082.23--0.288827.18-25.502.45155.000.4417-25.684.05
Mayinglong Pharmaceutical Group Co Ltd3.48bn482.37m10.82bn2.88k22.442.71--3.111.121.128.089.280.68726.428.531,208,299.009.7410.8211.6413.4744.8441.1814.1714.084.40--0.093633.04-11.207.38-7.4620.2658.3321.67
Changchun BCHT Biotechnology Co1.61bn414.29m10.91bn1.24k26.342.60--6.791.001.003.8810.150.31811.001.061,295,333.008.209.9510.2312.8187.5586.6325.7724.031.85--0.014710.5570.3012.36175.9831.3721.04--
Guobang Pharma Ltd5.71bn702.28m10.92bn4.23k15.501.39--1.911.261.2610.2614.030.55993.297.841,350,536.006.8710.368.8814.2423.8727.4912.2715.011.70--0.199218.24-6.4910.28-33.4923.7735.60--
Liaoning Chengda Biotechnology Co Ltd1.72bn332.10m11.36bn1.73k33.961.19--6.610.80320.80324.1622.930.17020.7631.43991,973.803.2910.633.4111.0180.5385.7419.3339.5617.44--0.001831.53-3.584.71-34.75-5.5639.78--
KPC Pharmaceuticals Inc7.55bn446.07m11.51bn5.05k25.662.08--1.520.59240.592410.037.310.78192.752.561,494,697.004.645.427.759.1340.8443.685.945.701.51--0.17235.75-6.991.6416.055.79-21.3314.87
Jiangxi Tianxin Pharmaceutical Co Ltd2.01bn557.43m12.07bn2.47k21.682.71--6.011.271.274.5810.180.39772.7510.26812,720.6011.04--11.82--41.64--27.76--6.39--0.0234---18.34---23.51------
Data as of Nov 01 2024. Currency figures normalised to Liaoning Chengda Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

6.38%Per cent of shares held by top holders
HolderShares% Held
GF Securities Asset Management (Guangdong) Co., Ltd.as of 11 Mar 20242.75m1.54%
Bosera Asset Management Co., Ltd.as of 30 Jun 20241.91m1.07%
Penghua Fund Management Co., Ltd.as of 30 Jun 20241.75m0.98%
The Vanguard Group, Inc.as of 02 Oct 20241.01m0.57%
China Southern Asset Management Co., Ltd.as of 30 Jun 2024970.49k0.54%
Yinhua Fund Management Co., Ltd.as of 30 Jun 2024665.57k0.37%
China Universal Asset Management Co., Ltd.as of 30 Jun 2024636.12k0.36%
E Fund Management Co., Ltd.as of 30 Jun 2024581.84k0.33%
Guotai Asset Management Co., Ltd.as of 30 Jun 2024566.38k0.32%
China Asset Management Co., Ltd.as of 30 Jun 2024559.89k0.31%
More ▼
Data from 30 Jun 2024 - 23 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.